Objective
Breast cancer is the major cause of cancer death in women worldwide, however significant geographical differences in morbidity can be observed. Studies of migrant populations have indicated that the genetic background only plays a tiny, if any, role in differences in breast cancer morbidity. The lower incidence of breast cancer in Asian population was associated with diet contents phytoestrogens.
Their potential health benefits include protection against hormone-dependent cancer, cardiovascular disease and osteoporosis. Resveratrol (3,4',5-trihydroxystilbene) has attracted considerable attention because its presence in diet and its wide spectrum of biological activity including antioxidative, antiplatelet, antifungal, phytoestrogenic, cardioprotective properties. Because of its structural similarity to diethylstilbestrol resveratrol can act as phytoestrogen. Many authors proposed this mechanism as explanation its action against breast cancer cells.
Moreover resveratrol acts as growth inhibitor of estrogen-independent cell lines. Piceatannol (3,3'4'5 trihydroxystilbene) is naturally occurring analog of resveratrol and as well as resveratrol has been classified as a phytoalexin. Many reports show that piceatannol interferes with neoplastic growth by modifying multiple cellular targets. While effects of resveratrol and piceatannol are well studied in various in vitro and animal models, up to now, little is known about their higher hydroxy analogs. Some findings suggest that they may be formed as the metabolites of resveratrol and piceatannol.
The main aims of this proposal are: estimation of cytotoxicity and apoptosis induction in estrogen receptor positive, negative and genetically transfected breast cancer cell lines by resveratrol analogs and investigation of metabolism of resveratrol analogs in these cell lines. Results will provide valuable information in design of new anticancer drugs as well as understanding and resolving problems of cancer drug resistance.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine cardiology cardiovascular diseases arteriosclerosis
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance
- medical and health sciences clinical medicine oncology breast cancer
- medical and health sciences health sciences nutrition
- medical and health sciences clinical medicine oncology leukemia
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2002-MOBILITY-11
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
POZNAN
Poland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.